A study by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), the Universidad Complutense (UCM), Universidad de Girona (UdG), and the Institute for Bioengineering of Catalonia (IBEC), working together with other international centers, has overcome one of the key hurdles to the use of nanorobots powered by enzymes called lipases.
The called LipoBots, which could be used for medical applications. LipoBots are capable to self-propulsate and to retain their enzymatic functionality in conditions similar to those of the human stomach.
This finding could pave the way for the development of highly targeted therapies against a number of diseases.
This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.
Cancer immunotherapy is based on using and strengthening the patient’s own immune system to recognize and fight tumor cells, without damaging healthy tissues.
Researchers from the Institute for Bioengineering of Catalonia (IBEC) have developed an innovative scaffold that allows muscle tissues growth at the millimetre scale in the laboratory.This technology opens the door to potential applications in fields such as organ transplantation and engineering, drug screening and disease modelling.
The study, published in the journal Virulence, finds that the class II ribonucleotide reductase enzyme (RNR) plays a key role in frequent lung infections, for example, those that occur in patients with cystic fibrosis.
